Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $22.08 million. The enterprise value is -$14.06 million.

Market Cap	22.08M
Enterprise Value	-14.06M

Important Dates

The last earnings date was Wednesday, August 6, 2025, before market open.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 12.20 million shares outstanding. The number of shares has increased by 256.57% in one year.

Current Share Class	12.20M
Shares Outstanding	12.20M
Shares Change (YoY)	+256.57%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.62%
Owned by Institutions (%)	20.52%
Float	7.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.06

Current Ratio	5.06
Quick Ratio	4.80
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-27.37

Financial Efficiency

Return on equity (ROE) is -491.67% and return on invested capital (ROIC) is -107.73%.

Return on Equity (ROE)	-491.67%
Return on Assets (ROA)	-35.95%
Return on Invested Capital (ROIC)	-107.73%
Return on Capital Employed (ROCE)	-100.29%
Revenue Per Employee	n/a
Profits Per Employee	-$1.22M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Q32 Bio has paid $21,000 in taxes.

Income Tax	21,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -94.96% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-94.96%
50-Day Moving Average	1.88
200-Day Moving Average	7.81
Relative Strength Index (RSI)	46.47
Average Volume (20 Days)	323,574

Short Selling Information

The latest short interest is 412,153, so 3.38% of the outstanding shares have been sold short.

Short Interest	412,153
Short Previous Month	556,802
Short % of Shares Out	3.38%
Short % of Float	5.37%
Short Ratio (days to cover)	0.12

Income Statement

Revenue	n/a
Gross Profit	-48.15M
Operating Income	-54.74M
Pretax Income	-65.02M
Net Income	-52.30M
EBITDA	-54.29M
EBIT	-54.74M
Earnings Per Share (EPS)	-$4.29

Full Income Statement

Balance Sheet

The company has $54.83 million in cash and $18.70 million in debt, giving a net cash position of $36.14 million or $2.96 per share.

Cash & Cash Equivalents	54.83M
Total Debt	18.70M
Net Cash	36.14M
Net Cash Per Share	$2.96
Equity (Book Value)	-12.24M
Book Value Per Share	-1.00
Working Capital	46.79M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$54.08 million and capital expenditures -$60,000, giving a free cash flow of -$54.14 million.

Operating Cash Flow	-54.08M
Capital Expenditures	-60,000
Free Cash Flow	-54.14M
FCF Per Share	-$4.44

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-256.57%
Shareholder Yield	-256.57%
Earnings Yield	-236.91%
FCF Yield	-245.24%

Analyst Forecast

The average price target for Q32 Bio is $24.00, which is 1,225.97% higher than the current price. The consensus rating is "Hold".

Price Target	$24.00
Price Target Difference	1,225.97%
Analyst Consensus	Hold
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1